Status Epilepticus (SE) is a neurological condition characterized by anomalous brain activity, causing repetitive seizures lasting for more than 5 min or periods of unusual behavior without returning to a normal level of consciousness between episodes. Chitosan has shown various pharmaceutical benefits, particularly in intranasal administration. In the current manuscript, novel ultra-deformable vesicles (fluidized spanlastics) loaded with lacosamide (LCM), a model anti-epileptic drug, were formulated and compared with their chitosan containing counterparts. The formed vesicles were assessed for their particle size (PS), zeta potential (ZP), entrapment efficiency (EE%) and storage stability. Surface morphology, pH and viscosity measurements, in-vitro release study and release kinetics, and ex-vivo permeation across nasal sheep mucosa were carried out on the optimized formulations. The bio-distribution and pharmacokinetic studies were performed using the radioiodinated-LCM (131I-LCM) utilizing different routes of administration to assess the in-vivo performance of intravenous solutions (IVs), intranasal solutions (INs) and the intranasal administered optimized formula (INFS). LCM-vesicles showed PS ranging from 109.90 to 418.4 nm, negative ZP values ranging from −28.00 to −48.30 mV in case of regular vesicles and shifted to +16.70 to +18.72 mV in case of chitosan coated vesicles, high EE% values having a range of 65.76–97.25 % and good storage stability properties. The optimized formulation showed spherical shape and enhanced ex-vivo permeation approximately 4-fold higher compared to LCM solution. The results of the in-vivo study demonstrated that the brain/blood ratio (B/B) of INs was 3.3-fold higher than IVs and INs of 131I-LCM in the first 5 min. Accordingly, the prepared system has been shown to possess a promising potential for brain diagnosis and/or therapy.
Read full abstract